Value
7.7/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 6.8 |
| Fwd P/E | 5.7 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 22.4x
- ▸PEG: 0.11
- ▸Attractively valued
LEGN · Why this verdict
Why Legend Biotech (LEGN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow is negative at roughly -5% of revenue, all profitability margins score at or near zero, and the overall quality profile falls well below the minimum threshold for investment-grade consideration — the company is not yet self-funding its growth. Quality breakdown | The quality deficit reverses if the company achieves positive operating cash flow for 2 consecutive quarters over the next 12 months. | →Stable |
| CounterCash-burning growth companies that are successfully scaling commercial products can reach cash-flow breakeven faster than consensus models anticipate, and current balance sheet liquidity (current ratio 7.4) provides meaningful runway. | ||
Revenue is growing at 56% year over year, among the strongest growth profiles in the biotech space, with a PEG ratio of 0.14 suggesting the market has not yet fully priced in the growth runway. Growth breakdown | Over 12 months, revenue growth sustains above 40% year over year and the forward earnings multiple begins to converge toward a level more consistent with the growth rate. | →Stable |
| CounterHigh-growth biotechs frequently see deceleration as the addressable patient population is penetrated; a single clinical or reimbursement setback could reset growth expectations sharply lower. | ||
With roughly 46% upside to the analyst consensus target and a reward-to-risk ratio above 6-to-1, the price geometry is meaningfully asymmetric in favor of buyers at the current level. Price targets | The stock closes more than half the gap to the $51.84 analyst price target within 12 months, confirming that the asymmetry is being realized. | →Stable |
| CounterAnalyst targets on pre-profit biotechs are highly sensitive to clinical read-outs and commercialization milestones; targets can compress rapidly if pipeline progress disappoints. | ||
The company has missed earnings estimates in three of the past four quarters, with the two older misses at -196% and -62% respectively — indicating that management guidance or analyst models have consistently underestimated losses. Earnings | The miss pattern reverses if the company beats or meets estimates in 2 of the next 3 quarters, demonstrating improving forecast discipline. | →Stable |
| CounterThe most recent quarter produced a 16% beat, which may signal the worst of the guidance misalignment is behind the company as the commercial ramp matures and loss rates become more predictable. | ||
Free cash flow is negative at roughly -5% of revenue, all profitability margins score at or near zero, and the overall quality profile falls well below the minimum threshold for investment-grade consideration — the company is not yet self-funding its growth.
→StableQuality breakdown
- Expectation
- The quality deficit reverses if the company achieves positive operating cash flow for 2 consecutive quarters over the next 12 months.
CounterCash-burning growth companies that are successfully scaling commercial products can reach cash-flow breakeven faster than consensus models anticipate, and current balance sheet liquidity (current ratio 7.4) provides meaningful runway.
Revenue is growing at 56% year over year, among the strongest growth profiles in the biotech space, with a PEG ratio of 0.14 suggesting the market has not yet fully priced in the growth runway.
→StableGrowth breakdown
- Expectation
- Over 12 months, revenue growth sustains above 40% year over year and the forward earnings multiple begins to converge toward a level more consistent with the growth rate.
CounterHigh-growth biotechs frequently see deceleration as the addressable patient population is penetrated; a single clinical or reimbursement setback could reset growth expectations sharply lower.
With roughly 46% upside to the analyst consensus target and a reward-to-risk ratio above 6-to-1, the price geometry is meaningfully asymmetric in favor of buyers at the current level.
→StablePrice targets
- Expectation
- The stock closes more than half the gap to the $51.84 analyst price target within 12 months, confirming that the asymmetry is being realized.
CounterAnalyst targets on pre-profit biotechs are highly sensitive to clinical read-outs and commercialization milestones; targets can compress rapidly if pipeline progress disappoints.
The company has missed earnings estimates in three of the past four quarters, with the two older misses at -196% and -62% respectively — indicating that management guidance or analyst models have consistently underestimated losses.
→StableEarnings
- Expectation
- The miss pattern reverses if the company beats or meets estimates in 2 of the next 3 quarters, demonstrating improving forecast discipline.
CounterThe most recent quarter produced a 16% beat, which may signal the worst of the guidance misalignment is behind the company as the commercial ramp matures and loss rates become more predictable.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Legend Biotech is a high-growth clinical-stage company delivering 56% year-over-year revenue expansion and a risk/reward ratio above 6-to-1 to analyst consensus targets, but persistent free cash flow burn, three earnings misses in the past four quarters, and quality metrics that fall well below investment-grade thresholds make this a speculative setup requiring careful position sizing.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 7.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.4 |
| FCF quality | 0.0 |
| Moat | 6.5 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -5% of revenue
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 56% YoY
Momentum
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 8.2 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 5.0 |
| Volume | 0.1 |
- ▸Oversold in uptrend (RSI 27)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.2 |
| Price target | 10.0 |
| erm sentiment | 5.1 |
- ▸Analyst upside: 91%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.3 |
| quality rank | 4.8 |
| growth rank | 7.1 |
Technical
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.5 |
| support resistance | 7.4 |
| 52w position | 3.2 |
Risk (lower is worse)
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.7 |
| days to cover | 5.8 |
| volatility | 0.0 |
| put call | 9.1 |
| implied vol | 0.5 |
| beta | 10.0 |
| debt equity | 8.4 |
- ▸High short interest justified: 18%
- ▸High IV: 77%
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:4.7>=4.5
- ASYMMETRY:5.3>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:38d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- MOMENTUM:4.7<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
5.30
Upside
+66.5%
Downside
12.6%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Growth at 10.0, Value at 7.7, and Sentiment at 7.5; the weakest are Catalyst at 2.5, Quality at 3.1, and Momentum at 4.7. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 5.30 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Hypergrowth Revenue Trajectory
Trip ifRevenue growth decelerates below 25% year over year for 2 consecutive quarters.
- P2Favorable Risk Reward Geometry
Trip ifAnalyst consensus price target compresses below $40, reducing upside to less than 13% from current levels.
- P3Cash Burn Quality Deficit
Trip ifFree cash flow remains negative and deteriorates beyond -15% of revenue for 2 consecutive quarters.
- P4Earnings Miss Pattern
Trip ifEPS surprise falls below -50% for 2 consecutive quarters.